BeOne Medicines (ONC) Preferred Stock Liabilities (2015)
BeOne Medicines (ONC) reported Preferred Stock Liabilities of $176.1 million for Q4 2015.
BeOne Medicines (ONC) has 1 years of Preferred Stock Liabilities data on file, last reported at $176.1 million in Q4 2015.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $176.1 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $176.1 million (changed N/A YoY) and the FY2015 annual result came in at $176.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $176.1 million in Q4 2015 per ONC's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $176.1 million in Q4 2015 and bottomed at $176.1 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | BeOne Medicines | - | - | 1.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 176.08 Mn |